{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:12:18Z","timestamp":1793301138127,"version":"4.5.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Withdrawal symptoms are common upon discontinuation of psychiatric medications. Catatonia, a neuropsychiatric condition proposed to be associated with gamma-aminobutyric acid (GABA) hypoactivity due to its robust response to benzodiazepines, has been described as a withdrawal syndrome in case reports but is not a well-recognized phenomenon. The authors undertook a review of withdrawal catatonia with an aim to understand its presentation as well as the medications and psychoactive substances it is associated with. The review identified 55 cases of withdrawal catatonia, the majority of which occurred upon discontinuation of benzodiazepines (24 cases) and discontinuation of clozapine (20 cases). No other antipsychotic medications were identified as having been associated with the onset of a catatonic episode within 2 weeks following their discontinuation. Increasing GABA activity and resultant GABA receptor adaptations with prolonged use is postulated as a shared pharmacological mechanism between clozapine and benzodiazepines that underlie their association with withdrawal catatonia. The existing evidence for clozapine\u2019s activity on the GABA system is reviewed. The clinical presentations of benzodiazepine withdrawal catatonia and clozapine withdrawal catatonia appear to differ and reasons for this are explored. One reason is that benzodiazepines act directly on GABA<jats:sub>A<\/jats:sub> receptors as allosteric agonists, while clozapine has more complex and indirect interactions, primarily through effects on receptors located on GABA interneurons. Another possible reason for the difference in clinical presentation is that clozapine withdrawal catatonia may also involve receptor adaptations in non-GABA receptors such as dopamine and acetylcholine. The findings from our review have implications for the treatment of withdrawal catatonia, and treatment recommendations are provided. Further research understanding the uniqueness of clozapine withdrawal catatonia among antipsychotic medication may give some insight as to clozapine\u2019s differential mechanism of action.<\/jats:p>","DOI":"10.1038\/s41398-018-0192-9","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T16:23:58Z","timestamp":1533054238000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["Review of withdrawal catatonia: what does this reveal about clozapine?"],"prefix":"10.1038","volume":"8","author":[{"given":"Matthew","family":"Lander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Bastiampillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitender","family":"Sareen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"key":"192_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyt.2014.00181","volume":"5","author":"P Sienaert","year":"2014","unstructured":"Sienaert, P., Dhossche, D. M., Vancampfort, D., De Hert, M. & Gazdag, G. A clinical review of the treatment of catatonia. Front Psychiatry 5, 1\u20139 (2014).","journal-title":"Front Psychiatry"},{"key":"192_CR2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2190\/X0FF-VU7G-QQP7-L5V7","volume":"25","author":"JM Hawkins","year":"1995","unstructured":"Hawkins, J. M., Archer, K. J., Strakowski, S. M. & Keck, P. E. Jr. Somatic treatment of catatonia. Int. J. Psychiatry Med. 25, 345\u2013369 (1995).","journal-title":"Int. J. Psychiatry Med."},{"key":"192_CR3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/schbul\/sbp141","volume":"36","author":"PI Rosebush","year":"2010","unstructured":"Rosebush, P. I. & Mazurek, M. F. Catatonia and its treatment. Schizophr. Bull. 36, 239\u2013242 (2010).","journal-title":"Schizophr. Bull."},{"key":"192_CR4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/2319-4170.107162","volume":"36","author":"YC Huang","year":"2013","unstructured":"Huang, Y.-C., Lin, C.-C., Hung, Y.-Y. & Huang, T.-L. Rapid relief of catatonia in mood disorder by lorazepam and diazepam. Biomed. J. 36, 35\u201339 (2013).","journal-title":"Biomed. J."},{"key":"192_CR5","first-page":"49","volume":"41","author":"H Payee","year":"1999","unstructured":"Payee, H., Chandrasekaran, R. & Raju, G. Catatonic syndrome: treatment response to lorazepam. Indian J. Psychiatry 41, 49\u201353 (1999).","journal-title":"Indian J. Psychiatry"},{"key":"192_CR6","unstructured":"Stahl, S. M. Stahl\u2019s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications 4th edn (Cambridge University Press, Cambridge, 2013)."},{"key":"192_CR7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/YCT.0b013e31815cbaa1","volume":"24","author":"E Esel","year":"2008","unstructured":"Esel, E. et al. The effects of electroconvulsive therapy on GABAergic function in major depressive patients. J. ECT 24, 224\u2013228 (2008).","journal-title":"J. ECT"},{"key":"192_CR8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1176\/appi.ajp.160.3.577","volume":"160","author":"G Sanacora","year":"2003","unstructured":"Sanacora, G. et al. Increased cortical GABA concentrations in depressed patients receiving ECT. Am. J. Psychiatry 160, 577\u2013579 (2003).","journal-title":"Am. J. Psychiatry"},{"key":"192_CR9","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/archpsyc.1977.01770200085010","volume":"34","author":"AJ Gelenberg","year":"1977","unstructured":"Gelenberg, A. J. & Mandel, M. R. Catatonic reactions to high-potency neuroleptic drugs. Arch. Gen. Psychiatry 34, 947\u2013950 (1977).","journal-title":"Arch. Gen. Psychiatry"},{"key":"192_CR10","first-page":"310","volume":"44","author":"G Johnson","year":"1983","unstructured":"Johnson, G. & Manning, D. Neuroleptic-induced catatonia: case report. J. Clin. Psychiatry 44, 310\u2013312 (1983).","journal-title":"J. Clin. Psychiatry"},{"key":"192_CR11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000118713","volume":"23","author":"V Kontaxakis","year":"1990","unstructured":"Kontaxakis, V., Vaidakis, N., Christodoulou, G. & Valergaki, H. Neuroleptic-induced catatonia or a mild form of neuroleptic malignant syndrome? Neuropsychobiology 23, 38\u201340 (1990).","journal-title":"Neuropsychobiology"},{"key":"192_CR12","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1592\/phco.2005.25.8.1156","volume":"25","author":"JH Tsai","year":"2005","unstructured":"Tsai, J.-H., Yang, P., Yen, J.-Y., Chen, C.-C. & Yang, M.-J. Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. Pharmacotherapy 25, 1156\u20131159 (2005).","journal-title":"Pharmacotherapy"},{"key":"192_CR13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1600-0447.1999.tb00980.x","volume":"99","author":"M Bahro","year":"1999","unstructured":"Bahro, M., K\u00e4mpf, C. & Strnad, J. Catatonia under medication with risperidone in a 61-year-old patient. Acta Psychiatr. Scand. 99, 223\u2013226 (1999).","journal-title":"Acta Psychiatr. Scand."},{"key":"192_CR14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3109\/00048678209161268","volume":"16","author":"RJ Perkins","year":"1982","unstructured":"Perkins, R. J. Catatonia: the ultimate response to fear? Aust. N. Z. J. Psychiatry 16, 282\u2013287 (1982).","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"192_CR15","unstructured":"Marks, I. Fears, Phobias, and Rituals: Panic, Anxiety, and Their Disorders. (Oxford University Press, New York, 1987)."},{"key":"192_CR16","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1037\/0033-295X.111.4.984","volume":"111","author":"AK Moskowitz","year":"2004","unstructured":"Moskowitz, A. K. \u2018Scared stiff\u2019: catatonia as an evolutionary-based fear response. Psychol. Rev. 111, 984\u20131002 (2004).","journal-title":"Psychol. Rev."},{"key":"192_CR17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/YCT.0000000000000134","volume":"30","author":"DM Dhossche","year":"2014","unstructured":"Dhossche, D. M. Vagal intimations for catatonia and electroconvulsive therapy. J. ECT 30, 111\u2013115 (2014).","journal-title":"J. ECT"},{"key":"192_CR18","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/0269881105053313","volume":"19","author":"SM Dursun","year":"2005","unstructured":"Dursun, S. M. et al. Clozapine monotherapy for catatonic schizophrenia: should clozapine be the treatment of choice, with catatonia rather than psychosis as the main therapeutic index? J. Psychopharmacol. 19, 432\u2013433 (2005).","journal-title":"J. Psychopharmacol."},{"key":"192_CR19","first-page":"36","volume":"18","author":"J Vattakatuchery","year":"2008","unstructured":"Vattakatuchery, J., Chinnaswamy, S. & Tranter, R. Combination of electroconvulsive therapy and clozapine in the treatment of malignant catatonia: a case report. Hong Kong J. Psychiatry 18, 36\u201338 (2008).","journal-title":"Hong Kong J. Psychiatry"},{"key":"192_CR20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/15622970701287369","volume":"10","author":"T Paparrigopoulos","year":"2009","unstructured":"Paparrigopoulos, T., Tzavellas, E., Ferentinos, P., Mourikis, I. & Liappas, J. Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine. World J. Biol. Psychiatry 10, 70\u201373 (2009).","journal-title":"World J. Biol. Psychiatry"},{"key":"192_CR21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1017\/S1742646411000082","volume":"8","author":"T Agadagba","year":"2011","unstructured":"Agadagba, T. & Bates, G. Treatment of schizophrenia complicated by catatonia with clozapine in a 16 year old asylum seeker. J. Psychiatr. Intensive Care 8, 47\u201353 (2011).","journal-title":"J. Psychiatr. Intensive Care"},{"key":"192_CR22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/0972-6748.110955","volume":"21","author":"S Chattopadhyay","year":"2012","unstructured":"Chattopadhyay, S., Saha, I., Dan, A. & Bhattacharyya, K. Clozapine responsive catatonia: a series of five cases. Ind. Psychiatry J. 21, 66\u201368 (2012).","journal-title":"Ind. Psychiatry J."},{"key":"192_CR23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1176\/jnp.23.2.jnp223","volume":"23","author":"ML England","year":"2011","unstructured":"England, M. L., Ongur, D., Konopaske, G. T. & Karmacharya, R. Catatonia in psychotic patients: clinical features and treatment response. J. Neuropsychiatry Clin. Neurosci. 23, 223\u2013226 (2011).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"192_CR24","first-page":"503601","volume":"2013","author":"M Buoli","year":"2013","unstructured":"Buoli, M., Dobrea, C., Caldiroli, A., Cremaschi, L., & Altamura, A. C. Augmentative asenapine in a recurrent manic catatonic patient with partial response to clozapine. Case Rep. Psychiatry 2013, 503601 (2013).","journal-title":"Case Rep. Psychiatry"},{"key":"192_CR25","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.1176\/appi.neuropsych.13010007","volume":"26","author":"V Ene-Stroescu","year":"2014","unstructured":"Ene-Stroescu, V., Nguyen, T. & Waiblinger, B. Successful treatment of catatonia in a young man with schizophrenia and progressive diffuse cerebral atrophy. J. Neuropsychiatry Clin. Neurosci. 26, E21\u2013E22 (2014).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"192_CR26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1176\/jnp.10.2.237","volume":"10","author":"O Rommel","year":"1998","unstructured":"Rommel, O., Tegenthoff, M., Widdig, W., Br\u00e4unig, P. & Malin, J.-P. Organic catatonia following frontal lobe injury: response to clozapine. J. Neuropsychiatry Clin. Neurosci. 10, 237\u2013238 (1998).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"192_CR27","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/j.1360-0443.1994.tb03743.x","volume":"89","author":"H P\u00e9tursson","year":"1994","unstructured":"P\u00e9tursson, H. The benzodiazepine withdrawal syndrome. Addiction 89, 1455\u20131459 (1994).","journal-title":"Addiction"},{"key":"192_CR28","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.psym.2015.12.007","volume":"57","author":"MA Oldham","year":"2016","unstructured":"Oldham, M. A. & Desan, P. H. Alcohol and sedative-hypnotic withdrawal catatonia: two case reports, systematic literature review, and suggestion of a potential relationship with alcohol withdrawal delirium. Psychosomatics 57, 246\u2013255 (2016).","journal-title":"Psychosomatics"},{"key":"192_CR29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/00048670802653398","volume":"43","author":"T Bastiampillai","year":"2009","unstructured":"Bastiampillai, T., Forooziya, F. & Dhillon, R. Clozapine-withdrawal catatonia. Aust. N. Z. J. Psychiatry 43, 283\u2013284 (2009).","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"192_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/2402731","volume":"2017","author":"J Bilbily","year":"2017","unstructured":"Bilbily, J., McCollum, B. & de Leon, J. Catatonia secondary to sudden clozapine withdrawal: a case with three repeated episodes and a literature review. Case Rep. Psychiatry 2017, 1\u201311 (2017).","journal-title":"Case Rep. Psychiatry"},{"key":"192_CR31","unstructured":"Association, A. P. Diagnostic and Statistical Manual of Mental Disorders 5th edn (American Psychiatric Publishing, Arlington, VA, 2013)."},{"key":"192_CR32","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/archneur.1989.00520420118033","volume":"46","author":"P Hauser","year":"1989","unstructured":"Hauser, P., Devinsky, O., De Bellis, M., Theodore, W. H. & Post, R. M. Benzodiazepine withdrawal delirium with catatonic features. Occurrence in patients with partial seizure disorders. Arch. Neurol. 46, 696\u2013699 (1989).","journal-title":"Arch. Neurol."},{"key":"192_CR33","first-page":"1277","volume":"40","author":"DJ Rapport","year":"1989","unstructured":"Rapport, D. J. & Covington, E. C. Motor phenomena in benzodiazepine withdrawal. Hosp. Community Psychiatry 40, 1277\u20131279 (1989).","journal-title":"Hosp. Community Psychiatry"},{"key":"192_CR34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00004714-199608000-00007","volume":"16","author":"PI Rosebush","year":"1996","unstructured":"Rosebush, P. I. & Mazurek, M. F. Catatonia after benzodiazepine withdrawal. J. Clin. Psychopharmacol. 16, 315\u2013319 (1996).","journal-title":"J. Clin. Psychopharmacol."},{"key":"192_CR35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/jnp.9.2.303","volume":"9","author":"BT Carroll","year":"1997","unstructured":"Carroll, B. T. Catatonia due to mixed sedative withdrawal. J. Neuropsychiatr. 9, 303\u2013304 (1997).","journal-title":"J. Neuropsychiatr."},{"key":"192_CR36","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0033-3182(97)71484-1","volume":"38","author":"SG Glover","year":"1997","unstructured":"Glover, S. G., Escalona, R., Bishop, J. & Saldivia, A. Catatonia associated with lorazepam withdrawal. Psychosomatics 38, 148\u2013150 (1997).","journal-title":"Psychosomatics"},{"key":"192_CR37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-2001-15188","volume":"34","author":"M Deuschle","year":"2001","unstructured":"Deuschle, M. & Lederbogen, F. Benzodiazepine withdrawal-induced catatonia. Pharmacopsychiatry 34, 41\u201342 (2001).","journal-title":"Pharmacopsychiatry"},{"key":"192_CR38","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1176\/jnp.2007.19.4.484","volume":"19","author":"BT Carroll","year":"2007","unstructured":"Carroll, B. T., Thomas, C., Tugrul, K. C., Cononcea, C. & Goforth, H. W. GABA A versus GABA B in olanzapine-induced tardive dystonia successfully. J. Neuropsychiatry Clin. Neurosci. 19, 484 (2007).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"192_CR39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1176\/appi.psy.50.3.289","volume":"50","author":"M Brown","year":"2009","unstructured":"Brown, M. & Freeman, S. Clonazepam withdrawal-induced catatonia. Psychosomatics 50, 289\u2013292 (2009).","journal-title":"Psychosomatics"},{"key":"192_CR40","first-page":"53","volume":"42","author":"EC Lauterbach","year":"2009","unstructured":"Lauterbach, E. C., Norris, B. K., Carter, W. G. & Shillcutt, S. D. Catatonia and CPK elevation in neurosyphilis: role of plural pharmacodynamic mechanisms. Psychopharmacol. Bull. 42, 53\u201363 (2009).","journal-title":"Psychopharmacol. Bull."},{"key":"192_CR41","first-page":"41","volume":"17","author":"BT Carroll","year":"2010","unstructured":"Carroll, B. T., Lee, J. W. Y., Appiani, F. & Thomas, C. The pharmacotherapy of catatonia. Prim. Psychiatry 17, 41\u201347 (2010).","journal-title":"Prim. Psychiatry"},{"key":"192_CR42","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3109\/00048674.2011.607131","volume":"45","author":"R Parameswaran","year":"2011","unstructured":"Parameswaran, R., Moore, K., Hannan, T. & Austin, M. Catatonia associated with temazepam withdrawal. Aust. N. Z. J. Psychiatry 45, 1006\u20131007 (2011).","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"192_CR43","first-page":"170","volume":"24","author":"JJ Amos","year":"2012","unstructured":"Amos, J. J. Lorazepam withdrawal- induced catatonia. Ann. Clin. Psychiatry 24, 170\u2013171 (2012).","journal-title":"Ann. Clin. Psychiatry"},{"key":"192_CR44","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1177\/0004867412444992","volume":"46","author":"BZ Wang","year":"2012","unstructured":"Wang, B. Z., Gupta, A., Bastiampillai, T. & Sani, F. Recurrent clozapine and lorazepam withdrawal psychosis with catatonia. Aust. N. Z. J. Psychiatry 46, 795\u2013796 (2012).","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"192_CR45","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ajp.2013.05.008","volume":"6","author":"T Sivakumar","year":"2013","unstructured":"Sivakumar, T., Yadav, A., Sood, M. & Khandelwal, S. K. Lorazepam withdrawal catatonia: a case report. Asian J. Psychiatr. 6, 620\u2013621 (2013).","journal-title":"Asian J. Psychiatr."},{"key":"192_CR46","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1097\/CCM.0000000000000053","volume":"42","author":"D Saddawi-Konefka","year":"2014","unstructured":"Saddawi-Konefka, D., Berg, S. M., Nejad, S. H. & Bittner, E. A. Catatonia in the ICU: an important and underdiagnosed cause of altered mental status. A case series and review of the literature. Crit. Care Med. 42, e234\u2013e241 (2014).","journal-title":"Crit. Care Med."},{"key":"192_CR47","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/JCP.0000000000000425","volume":"35","author":"B Holoyda","year":"2015","unstructured":"Holoyda, B. & Xiong, G. Catatonia associated with alprazolam discontinuation in a young man with cardiac cirrhosis. J. Clin. Psychopharmacol. 35, 735\u2013736 (2015).","journal-title":"J. Clin. Psychopharmacol."},{"key":"192_CR48","first-page":"1","volume":"2016","author":"TJ Peng","year":"2016","unstructured":"Peng, T. J., Patchett, N. D. & Bernard, S. A. Takotsubo cardiomyopathy and catatonia in the setting of benzodiazepine withdrawal. Case Rep. Cardiol. 2016, 1\u20133 (2016).","journal-title":"Case Rep. Cardiol."},{"key":"192_CR49","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00004714-199304000-00012","volume":"13","author":"MA Parsa","year":"1993","unstructured":"Parsa, M. A., Al-Lahham, Y. H., Ramirez, L. F. & Meltzer, H. Y. Prolonged psychotic relapse after abrupt clozapine withdrawal. J. Clin. Psychopharmacol. 13, 154\u2013155 (1993).","journal-title":"J. Clin. Psychopharmacol."},{"key":"192_CR50","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3109\/10401239709147792","volume":"9","author":"JWY Lee","year":"1997","unstructured":"Lee, J. W. Y. & Robertson, S. Clozapine withdrawal catatonia and neuroleptic malignant syndrome: a case report. Ann. Clin. Psychiatry 9, 165\u2013169 (1997).","journal-title":"Ann. Clin. Psychiatry"},{"key":"192_CR51","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/01.wnf.0000145506.99636.1b","volume":"27","author":"AW Yeh","year":"2004","unstructured":"Yeh, A. W., Lee, J. W. Y., Cheng, T. C., Wen, J. K. & Chen, W. H. Clozapine withdrawal catatonia associated with cholinergic and serotonergic rebound hyperactivity: a case report. Clin. Neuropharmacol. 27, 216\u2013218 (2004).","journal-title":"Clin. Neuropharmacol."},{"key":"192_CR52","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1440-1819.2006.01495.x","volume":"60","author":"YY Hung","year":"2006","unstructured":"Hung, Y.-Y., Yang, P.-S. & Huang, T.-L. Clozapine in schizophrenia patients with recurrent catatonia: report of two cases. Psychiatry Clin. Neurosci. 60, 256\u2013258 (2006).","journal-title":"Psychiatry Clin. Neurosci."},{"key":"192_CR53","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.eurpsy.2007.01.385","volume":"22","author":"A Kalogeropoulou","year":"2007","unstructured":"Kalogeropoulou, A. et al. Catatonia after abrupt discontinuation of chronic clozapine treatment. Eur. Psychiatry 22, S120\u2013S121 (2007).","journal-title":"Eur. Psychiatry"},{"key":"192_CR54","first-page":"402","volume":"13","author":"S Thanasan","year":"2010","unstructured":"Thanasan, S. & Jambunathan, S. Clozapine withdrawal catatonia or lethal catatonia in a schizoaffective patient with a family history of parkinsons disease. Afr. J. Psychiatry 13, 402\u2013404 (2010).","journal-title":"Afr. J. Psychiatry"},{"key":"192_CR55","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0033-3182(10)70710-6","volume":"51","author":"M Wadekar","year":"2010","unstructured":"Wadekar, M. & Syed, S. Clozapine-withdrawal catatonia. Psychosomatics 51, 355\u2013355.e2 (2010).","journal-title":"Psychosomatics"},{"key":"192_CR56","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/00048674.2011.619163","volume":"45","author":"R Dhillon","year":"2011","unstructured":"Dhillon, R., Bastiampillai, T., Tee, K. & Vanlint, A. Clozapine and associated QTc prolongation. Aust. N. Z. J. Psychiatry 45, 1098\u20131099 (2011).","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"192_CR57","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1601-5215.2011.00523.x","volume":"23","author":"S Kanagasundram","year":"2011","unstructured":"Kanagasundram, S. & Chengappa, K. N. R. Meningoencephalitis or clozapine withdrawal catatonia or both in a patient with schizophrenia. Acta Neuropsychiatr. 23, 85\u201387 (2011).","journal-title":"Acta Neuropsychiatr."},{"key":"192_CR58","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/00048674.2011.564135","volume":"45","author":"S Kumar","year":"2011","unstructured":"Kumar, S., Sur, S. & Singh, A. Catatonia following abrupt stoppage of clozapine. Aust. N. Z. J. Psychiatry 45, 499 (2011).","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"192_CR59","doi-asserted-by":"crossref","first-page":"275","DOI":"10.5455\/bcp.20120731051540","volume":"22","author":"C Cerit","year":"2012","unstructured":"Cerit, C., Tuzun, B., Akpinar, E. & Sahan, E. Clozapine withdrawal catatonia refractory to ECT: a case report. Bull. Clin. Psychopharmacol. 22, 275\u2013277 (2012).","journal-title":"Bull. Clin. Psychopharmacol."},{"key":"192_CR60","first-page":"1","volume":"24","author":"A Erol","year":"2013","unstructured":"Erol, A., Putg\u00fcl, G., Sert, E. & Mete, L. Clozapine-associated neuroleptic malignant syndrome followed by catatonia: a case report. Turk. Psikiyatr Derg. 24, 1\u20135 (2013).","journal-title":"Turk. Psikiyatr Derg."},{"key":"192_CR61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/542303","volume":"2013","author":"A Koch","year":"2013","unstructured":"Koch, A. et al. Catatonic dilemma in a 33-year-old woman: a discussion. Case Rep Psychiatry 2013, 1\u20133 (2013).","journal-title":"Case Rep Psychiatry"},{"key":"192_CR62","first-page":"27","volume":"5","author":"D Ariyasinghe","year":"2014","unstructured":"Ariyasinghe, D. & Abeyasinghe, R. Catatonia following abrupt discontinuation of clozapine. SL J. Psychiatry 5, 27\u201328 (2014).","journal-title":"SL J. Psychiatry"},{"key":"192_CR63","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.15cr10355","volume":"77","author":"I Koychev","year":"2016","unstructured":"Koychev, I., Hadjiphilippou, S., Lynch, J., Whelan, P. & MacCabe, J. Sudden-onset catatonia following clozapine withdrawal: a case report. J. Clin. Psychiatry 77, e899 (2016).","journal-title":"J. Clin. Psychiatry"},{"key":"192_CR64","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ajp.2017.08.009","volume":"30","author":"A Ingole","year":"2017","unstructured":"Ingole, A., Bastiampillai, T. & Tibrewal, P. Clozapine withdrawal catatonia, psychosis and associated neuroleptic malignant syndrome. Asian J. Psychiatr. 30, 96\u201397 (2017).","journal-title":"Asian J. Psychiatr."},{"key":"192_CR65","doi-asserted-by":"crossref","first-page":"465","DOI":"10.4088\/PCC.v09n0611a","volume":"9","author":"K Muralidharan","year":"2007","unstructured":"Muralidharan, K., Rajkumar, R. P., Rao, S. A. & Benegal, V. Catatonia as a presenting feature of alcohol withdrawal: a case report. Prim. Care Companion J. Clin. Psychiatry 9, 465 (2007).","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"192_CR66","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000319849","volume":"44","author":"JC Narayanaswamy","year":"2011","unstructured":"Narayanaswamy, J. C. et al. Catatonia in alcohol withdrawal: a case report. Psychopathology 44, 136 (2011).","journal-title":"Psychopathology"},{"key":"192_CR67","first-page":"CS129","volume":"15","author":"O Cottencin","year":"2009","unstructured":"Cottencin, O., Danel, T., Goudemand, M., Thomas, P. & Consoli, S. M. Catatonia recognition and treatment. Med Sci. Monit. 15, CS129\u2013CS131 (2009).","journal-title":"Med Sci. Monit."},{"key":"192_CR68","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/alcalc\/agr170","volume":"47","author":"PA Geoffroy","year":"2012","unstructured":"Geoffroy, P. A., Rolland, B. & Cottencin, O. Catatonia and alcohol withdrawal: a complex and underestimated syndrome. Alcohol Alcohol 47, 288\u2013290 (2012).","journal-title":"Alcohol Alcohol"},{"key":"192_CR69","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4103\/0976-500X.142449","volume":"5","author":"A Basu","year":"2014","unstructured":"Basu, A., Jagtiani, A. & Gupta, R. Catatonia in mixed alcohol and benzodiazepine withdrawal. J. Pharmacol. Pharmacother. 5, 261\u2013264 (2014).","journal-title":"J. Pharmacol. Pharmacother."},{"key":"192_CR70","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1176\/ajp.133.12.1454","volume":"133","author":"M Good","year":"1976","unstructured":"Good, M. Catatonialike symptomatology and withdrawal dyskenesias. Am. J. Psychiatry 133, 1454\u20131456 (1976).","journal-title":"Am. J. Psychiatry"},{"key":"192_CR71","first-page":"32","volume":"44","author":"R Campbell","year":"1983","unstructured":"Campbell, R., Schaffer, C. & Tupin, J. Catatonia associated with glutethimide withdrawal. J. Clin. Psychiatry 44, 32\u201333 (1983).","journal-title":"J. Clin. Psychiatry"},{"key":"192_CR72","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00004714-199904000-00019","volume":"19","author":"PI Rosebush","year":"1999","unstructured":"Rosebush, P. I., MacQueen, G. M. & Mazurek, M. F. Catatonia following gabapentin withdrawal. J. Clin. Psychopharmacol. 19, 188\u2013189 (1999).","journal-title":"J. Clin. Psychopharmacol."},{"key":"192_CR73","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.psym.2011.01.024","volume":"52","author":"MH Hsieh","year":"2011","unstructured":"Hsieh, M. H., Chen, T. C., Chiu, N. Y. & Chang, C. C. Zolpidem-related withdrawal catatonia: a case report. Psychosomatics 52, 475\u2013477 (2011).","journal-title":"Psychosomatics"},{"key":"192_CR74","first-page":"358","volume":"26","author":"MC Claussen","year":"2014","unstructured":"Claussen, M. C., Hassanpour, K., Jenewein, J. & Boettger, S. Catatonic stupor secondary to gamma-hydroxy-butyric acid (GHB)-dependence and -withdrawal syndrome. Psychiatr. Danub 26, 358\u2013359 (2014).","journal-title":"Psychiatr. Danub"},{"key":"192_CR75","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0447.2006.00787.x","volume":"114","author":"J Moncrieff","year":"2006","unstructured":"Moncrieff, J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr. Scand. 114, 3\u201313 (2006).","journal-title":"Acta Psychiatr. Scand."},{"key":"192_CR76","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00004714-199506000-00015","volume":"15","author":"JM Radford","year":"1995","unstructured":"Radford, J. M., Brown, T. M. & Borison, R. L. Unexpected dystonia while changing from clozapine to risperidone. J. Clin. Psychopharmacol. 15, 225\u2013226 (1995).","journal-title":"J. Clin. Psychopharmacol."},{"key":"192_CR77","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4088\/JCP.v59n0906","volume":"59","author":"S Ahmed","year":"1998","unstructured":"Ahmed, S. et al. Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. J. Clin. Psychiatry 59, 472\u2013477 (1998).","journal-title":"J. Clin. Psychiatry"},{"key":"192_CR78","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.pnpbp.2007.10.003","volume":"32","author":"KJ Skilbeck","year":"2008","unstructured":"Skilbeck, K. J., O\u2019Reilly, J. N., Johnston, G. A. R. & Hinton, T. Antipsychotic drug administration differentially affects [3H]muscimol and [3H]flunitrazepam GABA(A) receptor binding sites. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 492\u2013498 (2008).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"192_CR79","doi-asserted-by":"crossref","first-page":"231S","DOI":"10.1111\/j.1365-2125.1983.tb02295.x","volume":"16","author":"P Danneberg","year":"1983","unstructured":"Danneberg, P. & Weber, K. H. Chemical structure and biological activity of the diazepines. Br. J. Clin. Pharmacol. 16, 231S\u2013244S (1983).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"192_CR80","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/hup.2429","volume":"29","author":"BH Harvey","year":"2014","unstructured":"Harvey, B. H. & Slabbert, F. N. New insights on the antidepressant discontinuation syndrome. Hum. Psychopharmacol. Clin. Exp. 29, 503\u2013516 (2014).","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"192_CR81","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1124\/jpet.111.183285","volume":"339","author":"MM Reidenberg","year":"2011","unstructured":"Reidenberg, M. M. Drug discontinuation effects are part of the pharmacology of a drug. J. Pharmacol. Exp. Ther. 339, 324\u2013328 (2011).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"192_CR82","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.tins.2011.01.004","volume":"34","author":"KR Tan","year":"2011","unstructured":"Tan, K. R., Rudolph, U. & L\u00fcscher, C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci. 34, 188\u2013197 (2011).","journal-title":"Trends Neurosci."},{"key":"192_CR83","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pharmthera.2015.01.005","volume":"150","author":"WT O\u2019Connor","year":"2015","unstructured":"O\u2019Connor, W. T. & O\u2019Shea, S. D. Clozapine and GABA transmission in schizophrenia disease models: establishing principles to guide treatments. Pharmacol. Ther. 150, 47\u201380 (2015).","journal-title":"Pharmacol. Ther."},{"key":"192_CR84","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/BF00964003","volume":"8","author":"JH Skerritt","year":"1998","unstructured":"Skerritt, J. H. & Johnston, G. A. Interactions of some anaesthetic, convulsant, and anticonvulsant drugs at GABA-benzodiazepine receptor-ionophore complexes in rat brain synaptosomal membranes. Neurochem. Res. 8, 1351\u20131362 (1998).","journal-title":"Neurochem. Res."},{"key":"192_CR85","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0920-1211(97)00084-3","volume":"29","author":"CP Taylor","year":"1998","unstructured":"Taylor, C. P. et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 29, 233\u2013249 (1998).","journal-title":"Epilepsy Res."},{"key":"192_CR86","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2165\/00003495-200059040-00014","volume":"59","author":"KJ Holm","year":"2000","unstructured":"Holm, K. J. & Goa, K. L. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 59, 865\u2013889 (2000).","journal-title":"Drugs"},{"key":"192_CR87","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tips.2003.11.001","volume":"25","author":"CGT Wong","year":"2004","unstructured":"Wong, C. G. T., Gibson, K. M. & Snead, O. C. From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. Trends Pharmacol. Sci. 25, 29\u201334 (2004).","journal-title":"Trends Pharmacol. Sci."},{"key":"192_CR88","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0197-0186(99)00053-4","volume":"35","author":"SJ Mihic","year":"1999","unstructured":"Mihic, S. J. Acute effects of ethanol on GABAA and glycine receptor function. Neurochem. Int. 35, 115\u2013123 (1999).","journal-title":"Neurochem. Int."},{"key":"192_CR89","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane, J., Honigfeld, G., Singer, J. & Meltzer, H. Clozapine for the treatment resistant schizophrenic. Arch. Gen. Psychiatry 45, 789\u2013796 (1988).","journal-title":"Arch. Gen. Psychiatry"},{"key":"192_CR90","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1530-0277.1993.tb00735.x","volume":"17","author":"E Sanna","year":"1993","unstructured":"Sanna, E. et al. Chronic ethanol intoxication induces differential effects on GABAA and NMDA receptor function in the rat brain. Alcohol Clin. Exp. Res. 17, 115\u2013123 (1993).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"192_CR91","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1381612023396681","volume":"8","author":"AN Bateson","year":"2002","unstructured":"Bateson, A. N. Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr. Pharm. Des. 8, 5\u201321 (2002).","journal-title":"Curr. Pharm. Des."},{"key":"192_CR92","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tins.2008.02.005","volume":"31","author":"JE Lisman","year":"2008","unstructured":"Lisman, J. E. et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 31, 234\u2013242 (2008).","journal-title":"Trends Neurosci."},{"key":"192_CR93","doi-asserted-by":"crossref","first-page":"182","DOI":"10.5498\/wjp.v5.i2.182","volume":"5","author":"F Luchini","year":"2015","unstructured":"Luchini, F. et al. Electroconvulsive therapy in catatonic patients: efficacy and predictors of response. World J. Psychiatry 5, 182\u2013192 (2015).","journal-title":"World J. Psychiatry"},{"key":"192_CR94","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/sj.mp.4001987","volume":"12","author":"L Bragina","year":"2007","unstructured":"Bragina, L., Melone, M., Fattorini, G. & Conti, F. Clozapine upregulates the expression of the vesicular GABA transporter (VGAT) in rat frontal cortex. Mol. Psychiatry 12, 612\u2013613 (2007).","journal-title":"Mol. Psychiatry"},{"key":"192_CR95","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.neuropharm.2010.10.021","volume":"60","author":"A Guidotti","year":"2011","unstructured":"Guidotti, A. et al. Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology 60, 1007\u20131016 (2011).","journal-title":"Neuropharmacology"},{"key":"192_CR96","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1177\/0269881109348159","volume":"24","author":"F Hanisch","year":"2010","unstructured":"Hanisch, F., Friedemann, J. & Pillmann, F. Combined treatment with quetiapine and sertindole in therapy refractory insomnia after clozapine discontinuation. J. Psychopharmacol. 24, 1725\u20131726 (2010).","journal-title":"J. Psychopharmacol."},{"key":"192_CR97","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF02274897","volume":"246","author":"J Staedt","year":"1996","unstructured":"Staedt, J., Stoppe, G., Hajak, G. & R\u00fcther, E. Rebound insomnia after abrupt clozapine withdrawal. Eur. Arch. Psychiatry Clin. Neurosci. 246, 79\u201382 (1996).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"192_CR98","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1016\/S0014-2999(98)00285-4","volume":"349","author":"D Farnbach-Pralong","year":"1998","unstructured":"Farnbach-Pralong, D., Bradbury, R., Copolov, D. & Dean, B. Clozapine and olanzapine treatment decreases rat cortical and limbic GABA(A) receptors. Eur. J. Pharmacol. 349, R7\u2013R8 (1998).","journal-title":"Eur. J. Pharmacol."},{"key":"192_CR99","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0028-3908(99)00239-7","volume":"39","author":"FJ Michel","year":"2000","unstructured":"Michel, F. J. & Trudeau, L. E. Clozapine inhibits synaptic transmission at GABAergic synapses established by ventral tegmental area neurones in culture. Neuropharmacology 39, 1536\u20131543 (2000).","journal-title":"Neuropharmacology"},{"key":"192_CR100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/0269881107084002","volume":"22","author":"ZJ Daskalakis","year":"2008","unstructured":"Daskalakis, Z. J. et al. Increased cortical inhibition in persons with schizophrenia treated with clozapine. J. Psychopharmacol. 22, 203\u2013209 (2008).","journal-title":"J. Psychopharmacol."},{"key":"192_CR101","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.biopsych.2008.09.012","volume":"65","author":"SK Liu","year":"2009","unstructured":"Liu, S. K., Fitzgerald, P. B., Daigle, M., Chen, R. & Daskalakis, Z. J. The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia. Biol. Psychiatry 65, 503\u2013509 (2009).","journal-title":"Biol. Psychiatry"},{"key":"192_CR102","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.schres.2015.04.015","volume":"165","author":"TS Kaster","year":"2015","unstructured":"Kaster, T. S. et al. Clozapine potentiation of GABA mediated cortical inhibition in treatment resistant schizophrenia. Schizophr. Res. 165, 157\u2013162 (2015).","journal-title":"Schizophr. Res."},{"key":"192_CR103","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0028-3908(96)84629-6","volume":"35","author":"SB Kasture","year":"1996","unstructured":"Kasture, S. B., Mandhane, S. N. & Chopde, C. T. Baclofen-induced catatonia: modification by serotonergic agents. Neuropharmacology 35, 595\u2013598 (1996).","journal-title":"Neuropharmacology"},{"key":"192_CR104","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00004714-198612000-00027","volume":"6","author":"SL Pauker","year":"1986","unstructured":"Pauker, S. L. & Brown, R. Baclofen-induced catatonia. J. Clin. Psychopharmacol. 6, 387\u2013388 (1986).","journal-title":"J. Clin. Psychopharmacol."},{"key":"192_CR105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JCP.0b013e3181c9bfe6","volume":"30","author":"JWY Lee","year":"2010","unstructured":"Lee, J. W. Y. Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome. J. Clin. Psychopharmacol. 30, 3\u201310 (2010).","journal-title":"J. Clin. Psychopharmacol."},{"key":"192_CR106","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1755-5949.2010.00222.x","volume":"17","author":"M Nord","year":"2011","unstructured":"Nord, M. & Farde, L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci. Ther. 17, 97\u2013103 (2011).","journal-title":"CNS Neurosci. Ther."},{"key":"192_CR107","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","volume":"47","author":"P Seeman","year":"2002","unstructured":"Seeman, P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 47, 27\u201338 (2002).","journal-title":"Can. J. Psychiatry"},{"key":"192_CR108","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","volume":"340","author":"TPS Group","year":"1999","unstructured":"Group, T. P. S. Low-dose clozapine for the treatment of drug-induced psychosis in parkinson\u2019s disease. N. Engl. J. Med. 340, 757\u2013763 (1999).","journal-title":"N. Engl. J. Med."},{"key":"192_CR109","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-2999(96)00181-1","volume":"307","author":"P Salmi","year":"1996","unstructured":"Salmi, P. & Ahlenius, S. Further evidence for clozapine as a dopamine D1 receptor agonist. Eur. J. Pharmacol. 307, 27\u201331 (1996).","journal-title":"Eur. J. Pharmacol."},{"key":"192_CR110","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s002130050515","volume":"135","author":"I Ninan","year":"1998","unstructured":"Ninan, I. & Kulkarni, S. K. Partial agonistic action of clozapine at dopamine D2 receptcars in dopamine depleted animals. Psychopharmacol. (Berl.) 135, 311\u2013317 (1998).","journal-title":"Psychopharmacol. (Berl.)"},{"key":"192_CR111","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s002130050665","volume":"138","author":"DM Jackson","year":"1998","unstructured":"Jackson, D. M., Wikstr\u00f6m, H. & Liao, Y. Is clozapine an (partial) agonist at both dopamine D1 and D2 receptors? Psychopharmacology (Berlin) 138, 213\u2013214 (1998).","journal-title":"Psychopharmacology (Berlin)"},{"key":"192_CR112","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0079-6123(08)00910-2","volume":"172","author":"T Kuroki","year":"2008","unstructured":"Kuroki, T., Nagao, N. & Nakahara, T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog. Brain Res. 172, 199\u2013212 (2008).","journal-title":"Prog. Brain Res."},{"key":"192_CR113","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/archpsyc.1974.01760130040006","volume":"31","author":"S Snyder","year":"1974","unstructured":"Snyder, S., Greenberg, D. & Yamamura, H. I. Antischizophrenic drugs and brain cholinergic receptors. Arch. Gen. Psychiatry 31, 58\u201361 (1974).","journal-title":"Arch. Gen. Psychiatry"},{"key":"192_CR114","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0006-3223(95)00215-4","volume":"39","author":"C Verghese","year":"1996","unstructured":"Verghese, C., DeLeon, J., Nair, C. & Simpson, G. M. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biol. Psychiatry 39, 135\u2013138 (1996).","journal-title":"Biol. Psychiatry"},{"key":"192_CR115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/157015909790031184","volume":"7","author":"R Miller","year":"2009","unstructured":"Miller, R. Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: part II. Curr. Neuropharmacol. 7, 315\u2013330 (2009).","journal-title":"Curr. Neuropharmacol."},{"key":"192_CR116","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/archgenpsychiatry.2009.141","volume":"66","author":"M Fink","year":"2009","unstructured":"Fink, M. & Taylor, M. A. The catatonia syndrome: forgotten but not gone. Arch. Gen. Psychiatry 66, 1173\u20131177 (2009).","journal-title":"Arch. Gen. Psychiatry"},{"key":"192_CR117","unstructured":"Novartis Pharmaceuticals. Product monograph: Clozaril. 2015. https:\/\/www.novartis.ca\/sites\/www.novartis.ca\/files\/clozaril_scrip_e.pdf (accessed 14 November 2016)."},{"key":"192_CR118","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/acps.12241","volume":"130","author":"P Ifteni","year":"2014","unstructured":"Ifteni, P. et al. Effectiveness and safety of rapid clozapine titration in schizophrenia. Acta Psychiatr. Scand. 130, 25\u201329 (2014).","journal-title":"Acta Psychiatr. Scand."},{"key":"192_CR119","doi-asserted-by":"crossref","DOI":"10.1186\/1756-0500-7-264","volume":"7","author":"T Nissen","year":"2014","unstructured":"Nissen, T. & Wynn, R. The clinical case report: a review of its merits and limitations. BMC Res. Notes 7, 264 (2014).","journal-title":"BMC Res. Notes"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0192-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0192-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0192-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:24:06Z","timestamp":1671535446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0192-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["192"],"URL":"https:\/\/doi.org\/10.1038\/s41398-018-0192-9","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,31]]},"assertion":[{"value":"10 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"139"}}